Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

121.33
Delayed Data
As of Oct 20
 -14.63 / -10.76%
Today’s Change
96.93
Today|||52-Week Range
147.17
+4.82%
Year-to-Date
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval
Oct 20 / Zacks.com - Paid Partner Content
What's in the Cards for Amgen (AMGN) this Earnings Season?
Oct 20 / Zacks.com - Paid Partner Content
Celgene Down on Discontinued Crohn's Disease Drug Study
Oct 20 / Zacks.com - Paid Partner Content
Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?
Oct 20 / Zacks.com - Paid Partner Content
Tax Cut Progress Gives Wall Street Enough Fuel to End With More Records
Oct 20 / TheStreet.com - Paid Partner Content
Modest Gains Drive Wall Street to Trade at Records as Tax Progress Buoys Spirits
Oct 20 / TheStreet.com - Paid Partner Content
My (Brief) Takeaways and Observations
Oct 20 / TheStreet.com - Paid Partner Content
Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers
Oct 20 / TheStreet.com - Paid Partner Content
Tax Progress Boosts Wall Street, Major Indexes Trade Above Records
Oct 20 / TheStreet.com - Paid Partner Content
Stocks Set to Open With More Records as Trump Tax Reform Makes Progress
Oct 20 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close135.96
Today’s open124.50
Day’s range120.80 - 124.54
Volume27,765,072
Average volume (3 months)4,201,439
Market cap$106.4B
Dividend yield--
Data as of 4:14pm ET, 10/20/2017

Growth & Valuation

Earnings growth (last year)+28.35%
Earnings growth (this year)+23.33%
Earnings growth (next 5 years)+20.50%
Revenue growth (last year)+22.70%
P/E ratio37.7
Price/Sales8.51
Price/Book16.04

Competitors

 Today’s
change
Today’s
% change
BMYBristol-Myers Squibb-0.25-0.39%
GSKGlaxoSmithKline-0.26-0.63%
ABBVAbbVie-0.38-0.39%
SNYSanofi-0.51-1.02%
Data as of 4:02pm ET, 10/20/2017

Financials

Next reporting dateOctober 26, 2017
EPS forecast (this quarter)$1.88
Annual revenue (last year)$10.9B
Annual profit (last year)$2.0B
Net profit margin18.30%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark J. Alles
President &
Chief Operating Officer
Scott Andrew Smith
Corporate headquarters
Summit, New Jersey

Forecasts